A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
Tito BornerEvan D ShaulsonIan C TinsleyLauren M SteinCharles C HornMatthew R HayesRobert P DoyleBart C De JonghePublished in: Diabetes, obesity & metabolism (2020)
These findings highlight the potential therapeutic value of B12-Ex4 as a novel treatment for type 2 diabetes devoid of weight loss and with reduced adverse effects and better tolerance, but similar glucoregulation to current GLP-1R agonists.